Tempus AI, Inc. (TEM)

NMS – Real vaqt narxi. Valyuta: USD

46.95

-1.51 (-3.12%)

Yopilishda: May 12, 2026, 4:00 PM EDT

46.96

+0.01 (0.02%)

Bozordan keyin: May 12, 2026, 7:59 PM EDT

08.05.2026

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus AI, Inc. is positioned as a data-driven precision medicine leader, leveraging AI and a vast multi-modal patient database to drive diagnostics and biopharma partnerships. TEM's dual business model—genomic diagnostics and data licensing—creates network effects, with diagnostics feeding a proprietary data moat that underpins high-margin, scalable growth. Despite a 50% share price decline from highs and ongoing unprofitability, TEM's rising revenues, expanding gross margins, and robust contract pipeline support a strong buy rating for long-term investors.

08.05.2026

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The ag.

07.05.2026

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act.

07.05.2026

Tempus AI: Another Post-Earnings Dip Worth Buying

Tempus AI presents a compelling long-term opportunity, with strong data adoption and an expanding addressable market beyond Oncology. Q1 showed mixed results: robust Oncology testing, Hereditary weakness, decelerating revenue growth, but narrowing losses and gross margin expansion. Record $1.1B TCV and 126% net revenue retention underscore Tempus AI's durable value proposition and client stickiness.

06.05.2026

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Tempus AI posts narrower Q1 loss and strong 36% revenue growth, but shares slide after-market as operating loss and rising costs weigh on sentiment.

06.05.2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.

06.05.2026

Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript

Videolar

08.08.2025

Positive

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
TEM	BTIG Research	Buy	undefined >> $60	April 21st 2025
TEM	JP Morgan	Neutral	$50 >> $55	February 25th 2025
TEM	William Blair	Market Perform	undefined >> undefined	February 12th 2025

Press-relizlar

08.05.2026

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

07.05.2026

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act.

06.05.2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

05.05.2026

Tempus Reports First Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% MRD volume was ~6,500 tests in Q1 2026, up ~500% year-over-year Data and Applications revenue of $87.0.

Tempus AI, Inc. (TEM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempus AI, Inc. (TEM)

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus Reports First Quarter 2026 Results

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus Reports First Quarter 2026 Results

Search stocks

Tempus AI, Inc. (TEM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempus AI, Inc. (TEM)

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus Reports First Quarter 2026 Results

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Tempus Reports First Quarter 2026 Results